Ascentage Pharma Group International ( (HK:6855) ) has provided an announcement.
Ascentage Pharma Group International announced the successful closing of its American Depositary Shares offering, raising approximately US$126.36 million in gross proceeds. The net proceeds of US$112.89 million will be used to advance the clinical development of lisaftoclax and olverembatinib, fund research for other product candidates, and support general corporate purposes. This strategic move is expected to enhance Ascentage’s market positioning by accelerating its pipeline products’ regulatory approvals and commercial launches, particularly in China and the US.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. The company is known for its innovative approaches in drug development, particularly in China and the United States.
YTD Price Performance: -25.30%
Average Trading Volume: 2,486,247
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$11.6B
For detailed information about 6855 stock, go to TipRanks’ Stock Analysis page.